There is insufficient understanding of phage treatment of human infections ?

Mmmm !

The obvious thing to do

Link

To get going at long last!

Here

 pdf

  Et chapeau bas à Georgia!

Phage therapy is not for all bacterial infections

If we consider the  work experience  hoarded in the Ex-USSR countries about phage therapy such as a reference model and a good starting point then it is important does not forget that Phage therapy application can not diseregard  from the following points:

1-Phage therapy is not for all bacterial infections.
2-It is necessary to make a priority list of  all bacterial infections where Phage therapy could be effective.
In general  terms Phage Therapy Efficacy follows a decreasing gradient in the recovery chances.
Both recovery results and Phage presence are linked to the anatomical Site where a bacterial Infection is localized and active.
This decreasing Efficacy Gradient starts from the infective processes on the external surface of the Body to the infective processes on the intestinal mucosa , urinary tract and in the end, to the infective processes reached by bloodstream only.
When the infection site is localized on the skin we may have the best recovery chance by Phage therapy .




3-Phage therapy must be a timely remedy and easy . It is important does not lose time. For this raison it is necessary to have a national data bank on circulating bacteria and for sending to the hospital lab corresponding phages ready for use.

4-Phage therapy requires only Phage cocktails.  Phage cocktail must be well characterized and its effect monitored in the time.

Phage therapy new book

News from AmpliPhi

A world first: Pherecydes Pharma launches multicenter clinical study of phage therapy in serious burn victims

Pay attention: read!

How to chose and to plan a project of Phage therapy

 By these information it is possible in short time  to establish   on paper if there are some chanches of success.

It is indispensable to know of:

1-Bacterial diseases
a-social impact of the disease
b-economic impact of the disease
c-pathogenesis of the disease
 
2-Aetiological bacterial agent
a- presence of lytic phages  for this bacterial agent
b- the best route for Phage administration for this disease

 
From this link (http://www.rightdiagnosis.com) there is a list of types of bacterial diseases (but it is not exhaustive).

3-Check
1-first public written communication year ( journal,internet et cetera)
2-years passed from the first communication
3-how many dedicated clinical studies ?

At this moment there is a strong incoherence among point 3(1) and points 3(2),3(3).

Quality and Safety Requirements for Sustainable Phage Therapy Products

Suggested reading

Link

Link


  "This paper enumerates all phage therapy product related quality and safety risks known to the authors, as well as the tests that can be performed to minimize these risks, only to the extent needed to protect the patients and to allow and advance responsible phage therapy and research".

" To avoid the mistakes of the past (which lead to the current antibiotic resistance crisis), phage therapy products should not exclusively be developed and marketed as antibiotics, i.e., applying current pharmacoeconomic principles. Ideally, phage therapy should be coordinated and standardized (in a first instance) by national phage therapy centers, which operate under the supervision of relevant public health authorities and in interaction with private stakeholders".

 

Expert Consensus Quality and Safety Requirements for Sustainable Phage Therapy Products: 

 A. Production environment

 B. Production processes, equipment and materials

 C. Quality Assurance and Quality Control (QA/QC) specifications

       C.1. Host bacteria used in production (stock suspensions)

       C.2. Bacteriophages (Master Seed lots)

       C.3. Bacteriophages (Working Seed lots/Active Substances)       
       C.4. Finished products
 D. Shelf life of phage stock suspensions, working solutions and finished products (at recommended storage conditions)
 E. Surveillance
      

Bacterial virus found in Jerusalem sewage

Link

Killer Red project :engineer a temperate phage (specifically λ) to synthesize KillerRed in E. coli

My comment: an interesting work but Phage therapy demands more.

	1link 2link  3link  4link 5link  6link  7link

Now we all write about Phage therapy but where are the results?

The main target where there is a good chance of success for  phage therapy  is the skin  infection because  in this situation  there are few  adverse factors.


From

 

 The reasons are:
-easy medication
-easy check
- use of one Lytic Phage  or Phage cocktail
-direct contact with bacteria
-no antibodies
- easy to remove phage by washing
-et cetera


  In my old web site there is this document  from :

 
that now is unobtainable.

Comment:

 First we must   test  phage therapy in this  clinical area (and after in the others)

We must consolidate the theory but also to put it into the practice

It is  unsatisfactory to write  on Phage therapy only for publications

Why the PhagoBurn project is started ?   For the same reasons described above .

Main steps in Phage therapy procedure

In a Country: 

The epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: a lytic phage from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.

1.

2.

3.

 Commercial phage preparations